CollPlant Biotechnologies (NASDAQ:CLGN) Trading Down 0.8% – Time to Sell?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) shares were down 0.8% on Tuesday . The company traded as low as $3.85 and last traded at $3.89. Approximately 9,874 shares were traded during trading, an increase of 5% from the average daily volume of 9,436 shares. The stock had previously closed at $3.92.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on CLGN shares. EF Hutton Acquisition Co. I raised CollPlant Biotechnologies to a “strong-buy” rating in a report on Monday, August 5th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a report on Wednesday, August 21st.

CollPlant Biotechnologies Price Performance

The stock has a market cap of $44.09 million, a P/E ratio of -5.85 and a beta of 0.31. The company has a fifty day moving average of $4.82 and a 200 day moving average of $5.12.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its earnings results on Tuesday, August 20th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.70 million. CollPlant Biotechnologies had a negative return on equity of 65.98% and a negative net margin of 2,535.70%. As a group, analysts anticipate that CollPlant Biotechnologies Ltd. will post -1.44 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CollPlant Biotechnologies stock. Pinnacle Associates Ltd. boosted its position in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 6.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 564,360 shares of the company’s stock after purchasing an additional 33,905 shares during the period. Pinnacle Associates Ltd. owned 4.93% of CollPlant Biotechnologies worth $2,805,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.